Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Dianthus Therapeutics Q3 2026 Results: Net Loss of $46.6M, Loss Widens

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing product candidates such as claseprubart, DNTH212, and DNTH312. As of November 2, 2026, the company reported 56,312,712 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-46.6-36.8
EPS (diluted, $ a share)$-0.81$-0.97

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: DNTH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Dianthus Therapeutics, Inc.: key numbers

Share price
$86.98Close, Nov 17
Market cap
$4.9B
Shares outstanding
56.31MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Dianthus Therapeutics, Inc.

All →
5:32 PM ET Form 4
Insider Selling

Dianthus Therapeutics EVP, CFO & Cbo Ryan Savitz Sells $11.2M of Stock

Ryan Savitz, EVP, CFO & Cbo, sold 124,042 shares of Dianthus Therapeutics, Inc. at $85.16 to $91.59 a share (average $90.52) in 9 transactions, worth $11.2M in total between Nov 9, 2026 and Nov 12, 2026. Shares held after the trade: 0 (-100.0%).

Value
$11.2M
Shares
124,042
Average price
$90.52
Role
EVP, CFO & Cbo
Holding change
-100.0%
Trade date
Nov 9, 2026 to Nov 12, 2026
4:04 PM ET 8-K
Financial Results

Dianthus Therapeutics Financial Results

Dianthus Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, highlighting a cash position of approximately $1.2 billion. The company remains on track for Phase 2 MoMeNtum trial results in MMN in December 2026 and expects its current cash runway to fund operations into 2030.

“The Dianthus team continues to execute on our strategy to build a best-in-disease neuromuscular franchise with claseprubart across gMG, CIDP, and MMN, while advancing an exciting pipeline of potentially best-in-disease bifunctional fusion proteins with DNTH212 and DNTH312.”

Marino Garcia, Chief Executive Officer of Dianthus Therapeutics
4:36 PM ET Form 4
Insider Selling

Dianthus Therapeutics CAO Edward Carr Sells $2.03M of Stock

Edward Carr, CAO, sold 20,000 shares of Dianthus Therapeutics, Inc. at $100.43 to $104.39 a share (average $101.38) in 5 transactions, worth $2.03M in total on Sep 17, 2026. Shares held after the trade: 0 (-100.0%).

Value
$2.03M
Shares
20,000
Average price
$101.38
Role
CAO
Holding change
-100.0%
Trade date
Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.